Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

We invited teenagers to write miniature memoirs about meaningful moments in their lives. Read the 20 winning stories. By The Learning Network This year’s Super Bowl was likely the biggest ...

After hours: February 19 at 4:42:53 PM EST Loading Chart for PRPL ...